Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > The list of potential of Buyers
View:
Post by SundayMovies on Dec 22, 2022 10:56am

The list of potential of Buyers

Someone from this list will buy out ONCY:

https://www.oncolyticsbiotech.com/clinical-trials/collaborators
Comment by Noteable on Dec 22, 2022 11:13am
Two maor partners Pfizer, Merck KGaA are the only ones mentioned in co-development with ONCY.
Comment by Noteable on Dec 22, 2022 11:58am
December 22, 2022 - Pfizer takes an equity stake in ORIC Pharmaceuticals now giving the biotech enough cash to run operations through the first half of 2025 thanks to a $25 million equity investment and a new clinical partnership with Pfizer.   The pharma giant will work with the therapeutic resistance-focused biotech on ORIC-533, an oral small molecule inhibitor of CD73 in phase 2 ...more  
Comment by Noteable on Dec 22, 2022 12:45pm
Further to Pfizer's support of ORIC Pharmaceutical's CD73 inhibitor, recent studies demonstrated that the combination of intratumoral oncolytic reovirus, followed by targeted blockade of Programmed cell death protein 1 (PD-1) checkpoint inhibition and/or the immunomodulatory CD73/Adenosine system can enhance anti-tumor immunity, making ONCY's oncolytic virus pelareorep a logical ...more  
Comment by Noteable on Dec 22, 2022 12:53pm
As noted in an earlier posting ONCY's pelareorep down regulates HIF-1alpha, which is a sigificant inducer of TME hypoxia, as well as a down-regulator of the enzyme adenosine, which is a potent TME immunosuppressant, thus making ONCY's pelareorep a logical acquisition target for Pfizer.
Comment by itntdf on Dec 23, 2022 8:39am
although i don't believe they are a buyout candidate, adlai is also a development partner: Development Plan. As soon as reasonably practicable after the Effective Date, the Parties shall, acting through the JSC in accordance with the provisions of Clause 2, agree on and finalize the Development Plan, which shall focus on the development of Licensed Products ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities